TY  - BOOK
AU  - Yarden,Yosef
AU  - Elkabets,Moshe
ED  - SpringerLink (Online service)
TI  - Resistance to Anti-Cancer Therapeutics Targeting Receptor Tyrosine Kinases and Downstream Pathways
T2  - Resistance to Targeted Anti-Cancer Therapeutics,
SN  - 9783319679327
AV  - RC261-271 
U1  - 614.5999 23
PY  - 2018///
CY  - Cham
PB  - Springer International Publishing, Imprint: Springer
KW  - Cancer research
KW  - Cancer Research
N1  - Acceso multiusuario; Resistance of colorectal tumors to anti-EGFR antibodies -- Resistance of lung cancer to kinase inhibitors specific to EGFR or ALK -- Mechanisms of action and resistance of trastuzumab in breast cancer -- Mechanisms of resistance to molecular therapies targeting the HGF/MET axis -- RAF, MEK and ERK inhibitors as anti-cancer drugs: intrinsic and acquired resistance as a major therapeutic challenge -- Mechanisms of resistance to PI3K and AKT inhibitors -- Sensitivity and resistance to BH3 mimetics in cancer therapy -- Resistance mechanisms to cyclin-dependent kinase inhibitors -- Resistance to inhibitors of angiogenesis
N2  - This volume comprehensively covers the multiplicity and diversity of mechanisms underlying patient resistance to currently approved anti-cancer drugs, including tyrosine kinase inhibitors and monoclonal antibodies, blockers of growth factor receptors and their downstream pathways, which play essential functions in cancer progression. Each chapter will cover a specific group of targets and the cognate drugs, along with molecular modes of innate and evolving resistance
UR  - http://148.231.10.114:2048/login?url=https://doi.org/10.1007/978-3-319-67932-7
ER  -